Abstract. Activating mutations in KRAS drive pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Although mutant-selective KRAS inhibitors and pan-RAS inhibitors provide ...
Abstract:. Eileen M. O’Reilly, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York, NY, whose research focuses on therapies for pancreas cancer, spoke with Cancer ...
G. P. Warwick; The Mechanism of Action of Alkylating Agents. Cancer Res 1 September 1963; 23 (8_Part_1): 1315–1333. The term “alkylating agent” has been defined and a detailed discussion made of the ...
13Huntsman Cancer Institute, Salt Lake City, UT.
AbstractBackground:. Computational pathology has successfully incorporated artificial intelligence (AI) methodologies for various applications, including the predictions of therapeutic response, ...
Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, ...
Abstract. Breast cancer takes the first place in incidence and mortality among female cancer patients. Despite efforts being made in prevention and early detection, metastasis and resistance to ...
Search for other works by this author on: ...
Abstract 7901: Renal cancer early diagnosis using a novel B7-H3 targeted ultrasound contrast imaging
AbstractAim:. Cost-effective or accessible methods to detect kidney cancers, especially those with renal insufficiency, remain elusive. We propose ultrasound molecular imaging (UMI) using microbubbles ...
BigHat Biosciences, Inc., San Mateo, CA.
Search for other works by this author on: ...
The PK-TGI model could adequately characterize changes in tumor size as a function of R-DXd concentration as well as quantify the effect of target expression on tumor shrinkage. Combined with the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results